Wall Street analysts expect Vital Therapies, Inc. (NASDAQ:VTL) to announce earnings per share (EPS) of ($0.30) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Vital Therapies’ earnings. Vital Therapies reported earnings per share of ($0.32) during the same quarter last year, which suggests a positive year-over-year growth rate of 6.3%. The business is expected to issue its next quarterly earnings results on Thursday, November 2nd.

According to Zacks, analysts expect that Vital Therapies will report full-year earnings of ($1.29) per share for the current fiscal year, with EPS estimates ranging from ($1.33) to ($1.26). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.39) per share, with EPS estimates ranging from ($1.54) to ($1.20). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Vital Therapies.

Vital Therapies (NASDAQ:VTL) last issued its earnings results on Thursday, August 3rd. The company reported ($0.29) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.01. During the same period last year, the firm posted ($0.30) earnings per share.

Several brokerages have recently issued reports on VTL. Zacks Investment Research raised shares of Vital Therapies from a “sell” rating to a “hold” rating in a report on Friday, April 14th. ValuEngine lowered shares of Vital Therapies from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Finally, Raymond James Financial, Inc. began coverage on shares of Vital Therapies in a report on Thursday, May 18th. They issued an “outperform” rating and a $6.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. Vital Therapies presently has a consensus rating of “Hold” and an average price target of $8.00.

Shares of Vital Therapies (NASDAQ VTL) traded down 8.62% during mid-day trading on Friday, hitting $2.65. The stock had a trading volume of 160,025 shares. Vital Therapies has a 12-month low of $2.25 and a 12-month high of $6.58. The stock’s market capitalization is $111.85 million. The stock’s 50-day moving average price is $2.88 and its 200-day moving average price is $3.69.

ILLEGAL ACTIVITY WARNING: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/08/09/brokerages-anticipate-vital-therapies-inc-nasdaqvtl-to-announce-0-30-earnings-per-share.html.

In other news, Director Muneer A. Satter purchased 30,000 shares of the firm’s stock in a transaction dated Monday, June 12th. The stock was bought at an average price of $3.11 per share, with a total value of $93,300.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Muneer A. Satter purchased 10,000 shares of the firm’s stock in a transaction dated Tuesday, June 6th. The stock was purchased at an average cost of $3.19 per share, with a total value of $31,900.00. The disclosure for this purchase can be found here. Insiders bought a total of 108,400 shares of company stock valued at $338,153 in the last three months. 32.60% of the stock is owned by company insiders.

Institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. raised its position in shares of Vital Therapies by 1.8% in the first quarter. Goldman Sachs Group Inc. now owns 64,545 shares of the company’s stock valued at $258,000 after buying an additional 1,157 shares during the period. Bank of New York Mellon Corp raised its position in shares of Vital Therapies by 11.5% in the first quarter. Bank of New York Mellon Corp now owns 88,104 shares of the company’s stock valued at $352,000 after buying an additional 9,120 shares during the period. Victory Capital Management Inc. raised its position in shares of Vital Therapies by 1.2% in the second quarter. Victory Capital Management Inc. now owns 2,579,279 shares of the company’s stock valued at $7,480,000 after buying an additional 29,840 shares during the period. Blair William & Co. IL raised its position in shares of Vital Therapies by 67.2% in the second quarter. Blair William & Co. IL now owns 99,500 shares of the company’s stock valued at $289,000 after buying an additional 40,000 shares during the period. Finally, SG Americas Securities LLC purchased a new position in shares of Vital Therapies during the first quarter valued at about $167,000. 26.68% of the stock is owned by institutional investors.

Vital Therapies Company Profile

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Get a free copy of the Zacks research report on Vital Therapies (VTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related stocks with our FREE daily email newsletter.